Thu, Mar 5, 2015, 4:08 AM EST - U.S. Markets open in 5 hrs 22 mins


% | $
Quotes you view appear here for quick access.

Qiagen NV Message Board

  • pieightyeight pieightyeight Apr 4, 2011 6:39 PM Flag

    QIAGEN to Acquire Cellestis

    QIAGEN Makes Proposal to Acquire Australian Diagnostics Company Cellestis Limited
    -- QIAGEN to acquire Cellestis Limited (CST:AU) via a Scheme of Arrangement (the Scheme) for approximately A$341 million(1) (US$355 million), or A$3.55 per share
    -- Unanimous support from Cellestis board of directors(2);
    QIAGEN granted options to acquire up to 19.9% of Cellestis ordinary shares under certain circumstances, subject to regulatory approvals
    -- Acquisition provides QIAGEN with exclusive access to QuantiFERON® technology for high sensitivity, early disease detection not possible with other diagnostic approaches
    -- QuantiFERON® technology successfully commercialized with two marketed Cellestis tests for detection of latent tuberculosis (TB) and life-threatening CMV virus
    -- QIAGEN to expand QuantiFERON® portfolio, migrate technology to QIAsymphony and QIAensemble platforms and leverage synergies with current QIAGEN assay portfolio and pipeline
    -- Acquisition would accelerate QIAGEN's sales and adjusted EPS growth rates in 2012

    SortNewest  |  Oldest  |  Most Replied Expand all replies
24.79-0.12(-0.48%)Mar 4 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.